Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Li X, Jiang B, Gao T, Nian Y, Bai X, Zhong J, Qin L, Gao Z, Wang H, Ma X
Journal
European journal of medical research
Year
2024
Keywords:
Gut microbiota, Inflammatory, Inulin, Obesity, Polycystic ovary syndrome (PCOS)
CONTEXT: Polycystic ovary syndrome (PCOS), a common endocrine disorder in women of reproductive age, is closely associated with chronic low-grade inflammation and metabolic disturbances. In PCOS mice, dietary inulin has been demonstrated to regulate intestinal flora and inflammation. However, the efficacy of dietary inulin in clinical PCOS remains unclear. OBJECTIVE: The intestinal flora and related metabolic indexes of obese patients with polycystic ovary syndrome (PCOS) after 3 months of inulin treatment were analyzed. SETTING AND DESIGN: To analyze the intestinal flora and related metabolic indexes in healthy controls and obese patients with polycystic ovary syndrome after 3 months of inulin treatment. RESULTS: The results showed that dietary inulin improved sex hormone disorders, reduced BMI and WHR levels in obese women with PCOS. In addition, the inulin intervention reduced plasma TNF-α, IL-1β, IL-6, and MCP-1levels. Inulin intervention increased the abundance of Actinobacteria, Fusobacteria, Lachnospira, and Bifidobacterium, as well as decreased the ratio of F/B and the abundance of proteobacteria, Sutterella, and Enterobacter. Correlation analyses showed a strong relationship among plasma inflammatory factors, sex steroid hormones, and the intestinal flora of patients. CONCLUSIONS: Dietary inulin may improve obese PCOS women disease through the gut flora-inflammation-steroid hormone pathway. THE CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-IOR-17012281.
Experiment 1
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Polycystic ovary syndrome Cystic disease of ovaries,hyperandrogenemia,Multicystic ovaries,multicystic ovaries,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovarian Syndromes, Polycystic,Ovaries, Sclerocystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,PCO - Polycystic ovaries,Pco1,PCOD - Polycystic ovarian disease,PCOS,Pcos,PCOS - Polycystic ovarian syndrome,PCOS1,Polycystic ovarian disease,polycystic ovarian disease,Polycystic ovarian syndrome,Polycystic ovaries,polycystic ovaries,Polycystic ovaries (disorder),polycystic ovary,polycystic ovary syndrome,polycystic ovary syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary,Sclerocystic Ovary Syndrome,Stein Leventhal Syndrome,Stein-Leventhal synd.,Stein-Leventhal Syndrome,Stein-Leventhal syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal,Polycystic ovary syndrome
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Non-obese control group (NSD)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Obese control group (NFD)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- This group consists of obese patients with ≥ 25 kg/m2 body mass index (BMI).
- Group 0 sample size Number of subjects in the control (unexposed) group
- 20
- Group 1 sample size Number of subjects in the case (exposed) group
- 16
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Ion Torrent
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Signature 1
Source: Figure 3E
Description: Analysis of Biomarkers with significant differences between groups based on LDA Effect Size.
Abundance in Group 1: increased abundance in Obese control group (NFD)
| NCBI | Quality Control | Links |
|---|---|---|
| Allisonella | ||
| Parabacteroides distasonis | ||
| Howardella | ||
| [Ruminococcus] torques | ||
| Actinomyces massiliensis | ||
| TM7 phylum sp. oral clone FR058 | ||
| Megamonas |
Revision editor(s): Victoria
Signature 2
Source: Figure 3E
Description: Analysis of Biomarkers with significant differences between groups based on LDA Effect Size.
Abundance in Group 1: decreased abundance in Obese control group (NFD)
| NCBI | Quality Control | Links |
|---|---|---|
| Phocaeicola plebeius | ||
| unclassified Oscillospiraceae | ||
| Coprococcus eutactus |
Revision editor(s): Victoria
Experiment 2
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Obese control group (NFD)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Obese Polycystic Ovary Syndrome patients (FDB)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- This group consists of obese patients with ≥ 25 kg/m2 body mass index (BMI) who have polycystic ovary syndrome (PCOS).
- Group 0 sample size Number of subjects in the control (unexposed) group
- 16
- Group 1 sample size Number of subjects in the case (exposed) group
- 19
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 3F
Description: Analysis of Biomarkers with significant differences between groups based on LDA Effect Size.
Abundance in Group 1: increased abundance in Obese Polycystic Ovary Syndrome patients (FDB)
| NCBI | Quality Control | Links |
|---|---|---|
| Mediterraneibacter gnavus | ||
| Lactococcus | ||
| Prevotella corporis | ||
| Methylobacterium | ||
| Beijerinckiaceae | ||
| Phocaeicola plebeius |
Revision editor(s): Victoria
Signature 2
Source: Figure 3F
Description: Analysis of Biomarkers with significant differences between groups based on LDA Effect Size.
Abundance in Group 1: decreased abundance in Obese Polycystic Ovary Syndrome patients (FDB)
| NCBI | Quality Control | Links |
|---|---|---|
| Ligilactobacillus ruminis | ||
| Alloprevotella | ||
| bacterium LD2013 | ||
| Clostridium sp. MC 40 | ||
| Holdemanella | ||
| Bacteroides eggerthii |
Revision editor(s): Victoria
Experiment 3
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Obese Polycystic Ovary Syndrome patients (FDB) before inulin intervention
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Obese Polycystic Ovary Syndrome patients (FDA) after inulin intervention
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- This group consists of obese patients with ≥ 25 kg/m2 body mass index (BMI) who have polycystic ovary syndrome (PCOS) after 3 months of inulin intervention.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 19
- Group 1 sample size Number of subjects in the case (exposed) group
- 13
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 3G
Description: Analysis of Biomarkers with significant differences between groups based on LDA Effect Size.
Abundance in Group 1: increased abundance in Obese Polycystic Ovary Syndrome patients (FDA) after inulin intervention
| NCBI | Quality Control | Links |
|---|---|---|
| Lachnospira |
Revision editor(s): Victoria
Signature 2
Source: Figure 3G
Description: Analysis of Biomarkers with significant differences between groups based on LDA Effect Size.
Abundance in Group 1: decreased abundance in Obese Polycystic Ovary Syndrome patients (FDA) after inulin intervention
| NCBI | Quality Control | Links |
|---|---|---|
| Sutterella | ||
| Lactobacillaceae | ||
| Lactobacillus | ||
| Lactococcus | ||
| Enterobacter | ||
| Rhodospirillales | ||
| Lactococcus lactis |
Revision editor(s): Victoria
Experiment 4
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Obese control group (NFD)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 16
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 3H
Description: Analysis of Biomarkers with significant differences between groups based on LDA Effect Size.
Abundance in Group 1: increased abundance in Obese Polycystic Ovary Syndrome patients (FDA) after inulin intervention
Revision editor(s): Victoria
Signature 2
Source: Figure 3H
Description: Analysis of Biomarkers with significant differences between groups based on LDA Effect Size.
Abundance in Group 1: decreased abundance in Obese Polycystic Ovary Syndrome patients (FDA) after inulin intervention
| NCBI | Quality Control | Links |
|---|---|---|
| [Ruminococcus] torques | ||
| Bacteroides cellulosilyticus | ||
| Acidaminococcaceae | ||
| Christensenellaceae | ||
| Megasphaera | ||
| Ruminococcus bicirculans (ex Liu et al. 2021) |
Revision editor(s): Victoria
Retrieved from "https://bugsigdb.org/w/index.php?title=39217395&oldid=209299"
